

**2019 EMERGING THERAPIES FOR PBC, NASH, ESLD AND HCC SEMINAR SERIES**


**Louisville, Kentucky – February 9, 2019**

<b>Conference Location</b>	<b>Kosair Charities Clinical &amp; Translational Research Building Classroom 101 and 102</b> 505 S. Hancock Street Louisville, Kentucky 40202	<a href="https://louisville.edu/predictivemedicine/about/map/clinical-translational-research-building">https://louisville.edu/predictivemedicine/about/map/clinical-translational-research-building</a>
----------------------------	---	---

<b>Parking at the Conference</b>	There are parking lots for both the CTR building and the adjacent Health Science Center garage. There is also on-street, metered parking on all roads surrounding the CTR Building
----------------------------------	--

The Clinical & Translational Research (CTR) Building is located at the corner of Hancock Street and Mohammed Blvd adjacent to the campus of the University of Louisville School of Medicine. The seminar will be held in the classroom on the First Floor

**Driving Directions**



**Seminar Agenda and Syllabus Information**

Registration and breakfast begin at **7:30 a.m.** on the **CTR Building's First Floor**. Please check signage for any last minute room changes.

The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. WiFi will be available without charge.

<b>7:30 am</b>	<b>Registration, Continental Breakfast &amp; View Exhibits</b>
<b>8:00am</b>	<b>Welcome and Pre-Test</b>
<b>8:20 am</b>	<p><b>End Stage Liver Disease: Treatment, Managing Complications and Transplant</b></p> <ul style="list-style-type: none"> <li>• Staging, workup, and diagnosis of cirrhosis</li> <li>• Medical care of the patient with end stage liver disease</li> </ul> <p>Liver Transplantation</p> <ul style="list-style-type: none"> <li>• Listing Criteria and MELD Exceptions</li> </ul> <p><b>Case Study 1 – Cirrhosis and Encephalopathy</b></p>
<b>9:20 am</b>	<p><b>Hepatocellular Carcinoma</b></p> <ul style="list-style-type: none"> <li>• Screening diagnostic serum assays and imaging tests</li> </ul>

	<ul style="list-style-type: none"> <li>• Diagnosis without histology</li> <li>• Treatment and management options: Ablation, TACE and Surgery</li> </ul>
9:50 am	<b>Hepatocellular Carcinoma: New Systemic Treatment Options</b> <ul style="list-style-type: none"> <li>• Currently FDA Approved Therapies</li> <li>• New chemotherapy regimens in development and testing</li> <li>• Immunotherapy as the new MoA for HCC</li> </ul> <b>Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma</b>
10:30am	<b>Break &amp; View Exhibits</b>
10:45 am	<b>Primary Sclerosing Cholangitis (PSC)</b> <ul style="list-style-type: none"> <li>• Epidemiology</li> <li>• Ursodiol and Antibiotic Treatments</li> <li>• Predicting Outcomes and Improving Survival</li> </ul>
11:05 am	<b>New Treatments for PBC</b> <ul style="list-style-type: none"> <li>• Causes and Markers of PBC</li> <li>• Treatment Management</li> <li>• Ursodeoxycholic Acid (UDCA) and Obeticholic Acid</li> </ul>
11:35 am	<b>Malnutrition and Nutrition Support in Severe Alcoholic Hepatitis/Cirrhosis</b> <ul style="list-style-type: none"> <li>• The prevalence and implications of malnutrition</li> <li>• Therapy for malnutrition</li> </ul>
12:00 pm	<b>Luncheon &amp; View Exhibits</b>
1:00 pm	<b>The Best Use of Non-Invasive Imaging for Fibrosis Assessment</b> <ul style="list-style-type: none"> <li>• Technologies, Procedures and Outcomes</li> </ul>
1:30 pm	<b>NAFLD, LAL-D and NASH</b> <ul style="list-style-type: none"> <li>• Epidemiology and Demographics</li> <li>• Diagnosis and Evaluation</li> <li>• Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Causing Adult Fatty Liver</li> <li>• Conventional treatments</li> </ul>
2:15 pm	<b>Break &amp; View Exhibits</b>
2:30 pm	<b>NASH Treatments in Development</b> <ul style="list-style-type: none"> <li>• Life Style Changes</li> <li>• Drugs in Clinical development for NASH</li> </ul> <b>Case Study 3 - NASH Diagnosis and Treatment</b>
3:30 pm	<b>Post-test and Wrap-Up</b> <ul style="list-style-type: none"> <li>• <b>Session adjourns at 3:45pm</b></li> </ul>

#### **Attendee Cancellation, Substitution, Refund**

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

#### **Recording and Photography**

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

#### **Attendance Policies**

##### **Guest Attendance**

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

##### **Conference Modification or Cancellation**

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

---

**CME Information**

**Physicians (MD/DO)** - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)**<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses** - This program has been approved by the Kentucky Board of Nursing for 7.1 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-18-1030. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

**Nurse Practitioners and Physician Assistants** - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)<sup>TM</sup> organizations accredited by ACCME.

---

**CRAIG McCLAIN, MD**

Craig J. McClain, M.D., is an internationally distinguished clinician and scientist in the fields of gastroenterology, hepatology, alcohol abuse, nutrition, cytokine research, and hepatic drug metabolism. He is a Professor of Medicine at the University of Louisville School of Medicine.

Dr. McClain has made many seminal contributions to the field. In an early influential study published in the Journal of the American Medical Association (JAMA) in 1980, he described the deleterious interactions in the liver between alcohol and acetaminophen. In another landmark study, published in the journal Hepatology in 1989, Dr. McClain was the first to describe dysregulated cytokines in alcoholic hepatitis. This ground-breaking study is the second most cited liver pathobiology article in Hepatology over the past 25 years. Over time, Dr. McClain's work has increasingly focused on translational and interventional studies, including a seminal clinical study in 1993 on nutritional supplementation and alcoholic hepatitis patients

**MATTHEW C. CAVE, MD**

Dr. Matthew Cave is an Associate Professor of Medicine at the University of Louisville's School of Medicine. He also has joint appointments at Louisville's Department of Pharmacology and Toxicology, the Department of Biochemistry and Molecular Genetics and has an academic appointment at the Robley Rex Veterans Affairs Medical Center in Louisville, Kentucky.

Dr. Cave is active in many professional societies including: the American Gastroenterological Association (AGA); American Association for the Study of Liver Diseases (AASLD); the Kentucky Medical Association and the Southern Society for Clinical Investigation. Dr. Cave has been published extensively in esteemed medical journals and has written or collaborated on many medical texts.

**ASHUTOSH J. BARVE, MD, PhD**

Dr Barve is an Associate Professor of Medicine and the Director of the Liver Cancer Program at the University of Louisville School of Medicine. Board certified in both Internal Medicine and Gastroenterology, Dr. Barve received his medical degree from Seth G.S. Medical College and King Edward Memorial Hospital in Mumbai, India. His clinical areas of interest include liver cancer, transplant hepatology, therapeutic endoscopy and colon cancer screening. Dr. Barve has many clinical research projects, recent publications on liver disease and is active in AASLD.

**BARBRA CAVE, MSN, APRN, FNP-BC**

Barbra is a Family Nurse Practitioner and is Board Certified through the American Nurses Credentialing Center. She has been affiliated with the University of Louisville Division of Gastroenterology, Hepatology, & Nutrition since January 2012 where she had become experienced in caring for patients with a variety of GI and liver diseases. Since June 2015, she has been the lead Nurse Practitioner at the Jewish Hospital Hepatitis C Clinic.

Barbra serves a sub-investigator on numerous Gastroenterology and Hepatology clinical trials at the University of Louisville. She is currently a PhD student focusing on Hepatitis C and improving patient diagnosis and linkage to care and treatment.

---